Drug intelligence / Profile preview

botulinum toxin type A + recombinant human type III collagen

Development stage: Unknown
Lead developer: Shanxi Jinbo Bio-Pharmaceutical
Modality: Recombinant Proteins and Enzymes
Administration: Intramuscular, Intradermal

Overview

This combination therapy is an aesthetic medical intervention that pairs the neuromuscular blocking effects of botulinum toxin type A with the structural and regenerative properties of recombinant human type III collagen. Botulinum toxin type A (BoNT-A) is a neurotoxin that cleaves the SNAP-25 protein at the neuromuscular junction, thereby inhibiting the release of acetylcholine and inducing temporary muscle relaxation to smooth dynamic wrinkles. Recombinant human type III collagen is a bioengineered protein that replenishes the skin's extracellular matrix, providing structural support and promoting tissue repair to address static wrinkles and improve overall skin quality. This combination is primarily investigated for the treatment of periocular wrinkles (crow's feet), where it aims to provide a synergistic effect by addressing both the underlying muscular activity and the dermal structural deficiencies associated with aging.

Other names: BoNT-A + rhCol IIIbotulinum toxin type A combined with recombinant humanized type III collagen

Targets

SV2A (Synaptic vesicle glycoprotein 2A)COL (Collagen type XXI alpha 1 chain)SNAP25 (Synaptosome-associated protein 25)

Beyond the preview

Go deeper on botulinum toxin type A + recombinant human type III collagen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on botulinum toxin type A + recombinant human type III collagen.

Explore the full profile